UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 270

Sortiert nach

Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine

The international journal of neuropsychopharmacology, 2014-06, Vol.17 (6), p.859-869

2014

Volltextzugriff (PDF)

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

European archives of psychiatry and clinical neuroscience, 2020-09, Vol.270 (6), p.661-671

2020

Volltextzugriff (PDF)

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders

Schizophrenia research, 2009-09, Vol.113 (2), p.210-217

2009

Volltextzugriff (PDF)

Psychiatrie

1, 2013

Volltextzugriff (PDF)

Akathisia and Suicidal Ideation in First-Episode Schizophrenia

Journal of clinical psychopharmacology, 2012-10, Vol.32 (5), p.694-698

2012

Volltextzugriff (PDF)

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Psychopathology, 2012-01, Vol.45 (5), p.276-285

2012

Volltextzugriff (PDF)

Psychiatrie

Reprint 2013., 2013

Volltextzugriff (PDF)

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials

Wiener medizinische Wochenschrift, 2010-12, Vol.160 (21-22), p.547-556

2010

Volltextzugriff (PDF)

Hypericum extract WS® 5570 for depression - An overview

International journal of psychiatry in clinical practice, 2013-11, Vol.17 (S1), p.1-7

Gastpar, Markus

2013

Volltextzugriff (PDF)

The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients

The international journal of neuropsychopharmacology, 2007-10, Vol.10 (5), p.653-660

2007

Volltextzugriff (PDF)

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients

Basic & clinical pharmacology & toxicology, 2020-05, Vol.126 (5), p.444-447

2020

Volltextzugriff (PDF)

Sex-specific characteristics of mental disorders. Women are different

MMW Fortschritte der Medizin, 2007-06, Vol.149 (24), p.24

Gastpar, Markus

2007

Volltextzugriff (PDF)

Leitlinien – Wofür? Ein direkt Beteiligter kommentiert

Sucht, 2006-10, Vol.52 (5), p.347-347

Gastpar, Markus

2006

Volltextzugriff (PDF)

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial

International clinical psychopharmacology, 2010-09, Vol.25 (5), p.277

2010

Volltextzugriff (PDF)

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

Journal of clinical psychopharmacology, 2008-10, Vol.28 (5), p.593-595

2008

Volltextzugriff (PDF)

Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia

Psychiatric services (Washington, D.C.), 2012-01, Vol.63 (1), p.87-90

2012

Volltextzugriff (PDF)

Kommentar zum Beitrag von H. Elsner »Die disziplinarische Beendigung einer ambulanten Methadon-Substitution

Sucht, 2008-09, Vol.54 (4), p.240-241

Kuhlmann, Thomas

2008

Volltextzugriff (PDF)

Stellungnahme zum Editorial von H. Fleischmann »Ärzteschaft und suchtmedizinische Qualifikation – ein getrübtes Verhältnis« SUCHT (51) 2, S. 68/69

Sucht, 2005-06, Vol.51 (3), p.187-187

Gastpar, Markus

2005

Volltextzugriff (PDF)

Attention deficit hyperactivity disorder and borderline personality disorder

Progress in neuro-psychopharmacology & biological psychiatry, 2005-07, Vol.29 (6), p.865-877

2005

Volltextzugriff (PDF)

Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study

Pharmacopsychiatry, 2006-03, Vol.39 (2), p.66-75

2006

Volltextzugriff (PDF)

15. Wissenschaftliche Tagung, 31.03.– 02.04.2004 in Essen »Schutz- und Risikofaktoren in der Sucht

Sucht, 2004-02, Vol.50 (1), p.86-87

Gastpar, Markus

2004

Volltextzugriff (PDF)

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

European archives of psychiatry and clinical neuroscience, 2015-03, Vol.265 (2), p.107-116

2015

Volltextzugriff (PDF)

An early improvement threshold to predict response and remission in first-episode schizophrenia

British journal of psychiatry, 2010-06, Vol.196 (6), p.460-466

2010

Volltextzugriff (PDF)

Medication dependence is widespread. Do you also occasionally reach too quickly for the prescription pad? (interview by Dr. Thomas Meissner)

MMW Fortschritte der Medizin, 2007-05, Vol.149 (21), p.18

Gastpar, Markus T

2007

Volltextzugriff (PDF)

1 – 25 von 270

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(246)

Publikationsform

Buchkapitel
(152)
Artikel
(108)
Bücher
(5)
Reviews
(5)

Sprache

Deutsch
(172)
Englisch
(99)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Psychiatry
(216)
Life Sciences & Biomedicine
(81)
Science & Technology
(81)
Humans
(80)
Male
(63)
Female
(62)
Adult
(59)
Middle Aged
(42)
Biological And Medical Sciences
(38)
Medical Sciences
(38)
Pharmacology & Pharmacy
(27)
Neurosciences & Neurology
(26)
Psychiatric Status Rating Scales
(26)
Psychology. Psychoanalysis. Psychiatry
(25)
Treatment Outcome
(23)
Clinical Neurology
(22)
Schizophrenia
(22)
Follow-Up Studies
(21)
Psychopathology. Psychiatry
(21)
Aged
(20)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders

Psychiatrie

Akathisia and Suicidal Ideation in First-Episode Schizophrenia

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Psychiatrie

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials

Hypericum extract WS® 5570 for depression - An overview

The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients

Sex-specific characteristics of mental disorders. Women are different

Leitlinien – Wofür? Ein direkt Beteiligter kommentiert

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia

Kommentar zum Beitrag von H. Elsner »Die disziplinarische Beendigung einer ambulanten Methadon-Substitution

Stellungnahme zum Editorial von H. Fleischmann »Ärzteschaft und suchtmedizinische Qualifikation – ein getrübtes Verhältnis« SUCHT (51) 2, S. 68/69

Attention deficit hyperactivity disorder and borderline personality disorder

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression

Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study

15. Wissenschaftliche Tagung, 31.03.– 02.04.2004 in Essen »Schutz- und Risikofaktoren in der Sucht

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

An early improvement threshold to predict response and remission in first-episode schizophrenia

Medication dependence is widespread. Do you also occasionally reach too quickly for the prescription pad? (interview by Dr. Thomas Meissner)

Suchergebnisse filtern